Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 12—December 2020
Research

Trends in Population Dynamics of Escherichia coli Sequence Type 131, Calgary, Alberta, Canada, 2006–20161

Gisele Peirano2, Tarah Lynch2, Yasufumi Matsumara2, Diego Nobrega, Thomas J. Finn, Rebekah DeVinney, and Johann D.D. PitoutComments to Author 
Author affiliations: University of Calgary Cummings School of Medicine, Calgary, Alberta, Canada (G. Peirano, T. Lynch, T.J. Finn, R. De Vinney, J.D.D. Pitout); Alberta Precision Laboratories, Calgary (G. Peirano, T. Lynch, J.D.D. Pitout); Kyoto University Graduate School of Medicine, Kyoto, Japan (Y. Matsumara); University of Calgary, Calgary (D. Nobrega); University of Pretoria, Pretoria, South Africa (J.D.D. Pitout)

Main Article

Table 3

Factors associated with Escherichia coli sequence type 131 clades, Calgary, Alberta, Canada, 2006, 2012, and 2016*

Factor Clade
A, n = 34 B, n = 32 C0, n = 5 C1-non-M27, n = 121 C1-M27, n = 13 C2, n = 139 All, n = 344
QRDR mutation
gyrA S83L 29 (85)a,b 2 (6)c 2 (40)b,c 121 (100)d 13 (100)a,d 139 (100)d 306 (89)
gyrA D87N 5 (15)a 0a 1 (20)a 121 (100)b 13 (100)b 139 (100)b 279 (8)
parC S80I 5 (15)a 2 (6)a 1 (20)a 121 (100)b 13 (100)b 139 (100)b 281 (82)
parC E84V 1 (3)a 0a 1 (20)a 121 (100)b 13 (100)b 139 (100)b 275 (80)
parE I529L
30 (88)a
27 (84)a
5 (100)
121 (100)b
13 (100)
139 (100)b
335 (97)
β-lactamase
CTX-M-15 2 (6)a 1 (3)a 0a 1 (1)a 0a 93 (67)b 97 (28)
CTX-M-14 0a 0a 0 38 (31)b 0 1 (1)a 39 (11)
CTX-M-27 1 (3)a 0a 0 0a 7 (54)b 0a 8 (2)
CTX-M-55 2 (6) 0 0 0 0 0 2 (0.6)
CTX-M-198 0 0 0 1 (1) 0 0 1 (0.3)
NDM-5 0 0 0 0 0 1 (1) 1 (0.3)
OXA-1 0a 0a 0a 1 (1)a 0a 84 (6)b 85 (25)
OXA-9 0 0 0 0 0 1 (1) 1 (0.3)
SHV-12 0 0 0 0 0 2 (1) 2 (0.6)
TEM-1 29 (85)a,b 20 (63)a 4 (80)a,b 103 (85)b 1 (8)c 26 (19)c 183 (53)
TEM other 0 0 0 2 (2) 0 2 (1) 4 (1)
CMY-2
0
2 (6%)
0
1 (1)
0
0
3 (0.9)
Aminoglycoside-modifying enzyme
Aac(3)-IIa 0a 0a 0 2 (1)a 0a 57 (41)b 59 (17)
Aac(3))-IId 11 (32)a,b 15 (47)a 0 63 (52)a 0b,c 4 (3)c 93 (27)
aac(6')-Ib-cr 0a 0a 0a 2 (2)a 0a 84 (60)b 86 (25)
aadA1 0 2 6) 0 0 0 4 (3) 6 (2)
aadA16 0 0 0 1 (1) 0 1 (1) 2 (0.6)
aadA2 0a 14 (44)b 0 0a 0a 2 (1)a 16 ()
aadA5 23 (68)a 1 (3)b 3 (60)a,c 70 (58)a 7 (54)a,c 57 (41)c 161 (47)
ant(2′′)-Ia 0 0 0 0 0 5 (4) 5 (1)
aph(3′)-Ia 1 (3) 2 0 1 (11) 0 0 4 (1)
aph(3′′)-Ib 20 (59)a 3 (9)b 0 69 (57)a 5 (38) 26 (19)b 123 (36)
aph(3′)-IIa 0 1 (3) 0 1 (1) 0 0 2 (0.6)
Aph(6)-Ic 0 1 (3) 0 1 (1) 0 0 2 (0.6)
Aph(6)-Id
20 (59)a
3 (9)b
0
68 (56)a
5 (38)
25 (18)b
121 (35)
Other
qnrB 0 0 0 0 0 2 (1) 2 (0.6)
ARR-3 0 0 0 1 (1) 0 1 (1) 2 (0.6)
dfrA1 0 1 (3) 0 0 0 0 1 (0.3)
dfrA12 0a 13 (41)b 0 0a 0a 2 (1)a 15 (4)
dfrA14 1 (3) 0 0 0 0 8 12 (3)
dfrA17 22 (65)a 1 (3)b 3 (60)a 70 (58)a 7 (54)a 59 (42)a 162 (47)
dfrA27 0 0 0 1 (1) 0 1 (1) 2 (0.6)
dfrA5 0 1 (3) 0 0 0 0 1 (0.3)
sul1 22 (65) 15 (47) 3 (60) 69 (57) 6 (46) 63 (45) 178 (52)
sul2 20 (59)a 3 (9)b 0 70 (58)a 5 (38) 28 (20)b 126 (37)
sul3 0 1 (3) 0 0 0 0 1 (0.3)
tetA 19 (56)a 5 (16)b 0 61 (50)a 6 (4) 77 (55)a 168 (49)
tetB 2 (6) 3 (9) 0 2 (2) 0 3 (2) 10 (3)

*Values are no. (%). Rates followed by different superscript letters indicate significant differences between clades at the 5% level (adjusted for multiple comparisons).

Main Article

1Accepted as an oral presentation for the 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris, France, April 18–21, 2020.

2These authors contributed equally to this article.

Page created: August 05, 2020
Page updated: November 19, 2020
Page reviewed: November 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external